Introduction
Chronic renal disease progressing to end-stage renal failure is characterized by persistent accumulation and deposition of extracelluar matrix that leads to widespread tissue fibrosis. 1 Renal interstitial fibrosis is considered to be the commonly converging outcome of chronic renal diseases with a wide spectrum of diverse etiologies. 2 While tremendous progress has been made in delineating the cellular and molecular pathogenesis during last decades, the therapy of clinically chronic renal fibrosis remains to be extremely challenging. In addition, the incidence of end-stage renal failure is on the rise at a high rate worldwide. 3 Thus, developing a novel therapeutic strategy is necessary for more effective treatment of chronic renal fibrosis in patients.
Hepatocyte growth factor (HGF) is a potent renotropic protein that plays a critical role in promoting tubular repair and renal regeneration after injurious stimuli. [4] [5] [6] [7] In addition to the well-characterized mitogenic, motogenic, and tubulogenic properties, [8] [9] [10] HGF is demonstrated to be a potent survival factor protecting renal tubular epithelial cells from apoptosis. [11] [12] [13] [14] Recent studies also show its potential as a therapeutic agent for inhibition of tissue fibrosis. 15, 16 Consistent with this, studies from our laboratory and others also demonstrate that endogenous HGF is essential for preserving normal nephron structure and functions in the diseased kidneys. 17, 18 These results indicate that exogenous HGF may have a therapeutic role in preventing tissue fibrosis and renal dysfunction.
Because exogenous HGF is very unstable in blood circulation due to the rapid clearance by the liver, 19 it is difficult to sustain a high level of exogenous HGF in vivo by repeated injections of purified protein even at very short intervals. In addition, the progression of chronic renal fibrosis often is a slow process over long periods in humans. 2 In view of the fact that long-term therapy may be necessary, repeated injections of purified HGF protein are both inconvenient and extremely costly. To circumvent this problem, we recently developed an efficient approach to introduce exogenous HGF gene in vivo by systemic administration of naked plasmid vector. 20 This hydrodynamics-based in vivo gene transfer strategy results in a high level of exogenous HGF protein in the circulation, as well as in the liver and kidneys of normal adult animals. 20 Hence, this gene transfer approach may provide an efficient way to investigate the therapeutic potential of HGF for chronic renal fibrosis.
In this paper, we report the effects of exogenous HGF gene transfer on the progression of renal interstitial fibrosis in a mouse model of chronic renal disease induced by unilateral ureteral obstruction. Our results suggest that systemic administration of naked HGF plas-mid significantly ameliorated renal interstitial fibrosis in animals.
Results

Expression of human HGF in the obstructed kidneys after systemic administration of naked plasmid vector
To deliver exogenous HGF to the kidney under pathological conditions, we administered naked plasmid encoding human HGF cDNA driven under cytomegalovirus promoter (pCMV-HGF) by intravenous injections. Figure  1a illustrates the experimental scheme in which mice were injected through the tail vein before (day −1) and after (days 3 and 7) unilateral ureteral obstruction (UUO). Quantitative determination of human HGF using a specific enzyme-linked immunosorbent assay (ELISA) exhibited approximately 190 ng of exogenous HGF per mg of total tissue protein in the obstructed kidneys at day 3 after single injection of 20 g of pCMV-HGF plasmid per mouse (Figure 1b) . Following a second injection at day 3, renal human HGF increased to more than 340 ng/mg total proteins at day 7. A third injection at day 7 did not further increase, but sustained renal exogenous HGF protein in the obstructed kidneys at day 14 after UUO ( Figure 1b ). Of note, since the anti-HGF monoclonal antibody only detects human HGF and does not cross-react with endogenous mouse HGF, 20 the level of tissue HGF protein determined by this ELISA represents only exogenous human HGF derived from transgene expression. As expected, intravenous injection of empty pcDNA3 plasmid vector in an identical manner produced no human HGF in the kidneys at any given time point (Figure 1 ).
The expression of HGF transgene in the obstructed kidneys was independently confirmed by utilizing Western blot approach to detect human HGF protein. As shown in Figure 1c , whole tissue lysates either from normal kidneys of sham-operated animals or from the obstructed kidneys of UUO mice receiving empty vector injections exhibited no detectable human HGF protein. Under the same conditions, human HGF protein was readily detected in whole tissue lysates of the obstructed kidneys receiving pCMV-HGF plasmid injections (Figure 1c ). The levels of exogenous HGF in the obstructed kidneys were Gene Therapy significantly increased at day 7 and day 14 after UUO following second and third injections, respectively. Judged from the intensity of an adjacent band of the purified human recombinant HGF (5 ng), the relative abundance of human HGF in the obstructed kidneys at different time points following injections largely resembled the amounts of HGF protein determined by ELISA ( Figure  1b) .
Activation of mitogen-activated protein (MAP) kinase in the obstructed kidneys after expression of HGF transgene
To test the functionality of exogenous HGF in the obstructed kidneys, we investigated the activation of mitogen-activated protein (MAP) kinases following injection of HGF plasmid vector in vivo. This assay is based on the observation that the activation of extracellular signalregulated kinase-1 and -2 (Erk 1/2) is one of the principal signaling events of HGF actions on renal epithelial cells in vitro (data not shown). As shown in Figure 2 , activation of p44-MAP kinase (Erk1) and p42-MAP kinase (Erk2) was found in the obstructed kidney after pCMV-HGF plasmid injection. Compared with the sham-operated, normal kidneys, ureteral obstruction did not substantially alter the phosphorylated status of Erk 1/2 at the various time points examined (Figure 2 ). However, following administration of human HGF plasmid, significant induction in the phosphorylated status of Erk 1/2 was detected in the obstructed kidneys using a phosphospecific antibody. Time course studies revealed that activation of Erk1/2 kinases began at day 3 and was sustained at least to day 14, the longest time point tested, in the obstructed kidneys ( Figure 2 ). Because Erk1/2 activation is essential for various cellular activities, 21, 22 these results suggest that expression of exogenous HGF gene may initiate cascades of signal transduction pathway(s) leading to important functional consequences in the obstructed kidneys.
Expression of exogenous HGF gene inhibits ␣-smooth muscle actin (␣SMA) expression and myofibroblast activation
The obstructed kidneys displayed a progressive renal interstitial fibrosis characterized by myofibroblast activation, tubular atrophy and interstitial fibrogenesis. As shown in Figure 3 , renal expression of ␣SMA, an indicative marker for myofibroblast activation, was markedly induced in the obstructed kidneys at a very early stage. At day 3 after UUO, significant induction of ␣SMA expression was found in the obstructed kidneys from the mice receiving empty vector (Figure 3c ). The induction of ␣SMA was progressive and increased in a time-dependent manner. This dynamic pattern of ␣SMA expression manifests the course of renal myofibroblast activation and interstitial fibrogenesis typically seen in this model of chronic renal fibrosis disease. However, systemic administration of pCMV-HGF plasmid significantly inhibited ␣SMA expression in the obstructed kidneys. Figure 3a shows that the levels of ␣SMA in the obstructed kidneys at day 7 following pCMV-HGF plasmid injections were markedly suppressed compared with that following empty vector injections. Of note, the inhibition of ␣SMA expression was relatively consistent among each individual animal in the treatment group (Figure 3a ). In agreement with the Western blot data, immunohistochemical staining revealed that there was marked induction of ␣SMA staining in the obstructed kidneys in a timedependent fashion after UUO, and that mice receiving intravenous injection of pCMV-HGF plasmid displayed a much weaker ␣SMA staining in the obstructed kidneys (data not shown).
Exogenous HGF attenuates renal interstitial fibrosis
We next examined the effects of expression of HGF transgene on the progression of renal interstitial fibrosis in the obstructed kidneys. Figure 4 shows the morphological injury in the obstructed kidneys following intravenous injections of either pCMV-HGF or empty plasmid vector. Renal injury, characterized by tubular dilatation with epithelial atrophy, interstitial expansion with myofibroblast activation and matrix deposition, occurred in the early stage after UUO and was progressive in a time-dependent manner (Figure 4b, d ). Under the same conditions, expression of HGF transgene significantly attenuated these morphological injuries in the obstructed kidneys (Figure 4c, d) .
We further examined the expression and deposition of collagen I and fibronectin, two major components of interstitial extracellular matrix (ECM). Figure 5 shows the results of collagen I deposition in the obstructed kidneys as determined by an indirect immunofluorescence staining. As expected, the expression of collagen I was markedly and progressively increased in the obstructed kidneys following UUO (Figure 5b, d) . However, substantial inhibition of collagen I expression was clearly evident in the obstructed kidneys after HGF gene transfer ( Figure  5c, d) . Similar results were obtained for renal fibronectin expression ( Figure 6 ). Both Western blot analyses with whole kidney lysates ( Figure 6a ) and immunofluorescence staining (Figure 6b , c) exhibited a marked inhibition of fibronectin expression in the obstructed kidneys following HGF gene transfer, which is consistent with the notion that exogenous HGF inhibits interstitial matrix production and prevents renal fibrogenesis.
Exogenous HGF inhibits the expression of TGF-␤1 and its receptor in vivo
To gain insights into how exogenous HGF inhibits renal fibrosis, we examined the expression of TGF-␤1 and its type I receptor (T␤R-I) in the obstructed kidneys following systemic administration of HGF expression plasmid. Figure 7a shows the levels of TGF-␤1 protein determined by a specific ELISA in the obstructed kidneys at different time-points after UUO. Ureteral obstruction caused a marked increase in renal TGF-␤1 expression in a time- dependent way. Following intravenous injection of naked HGF plasmid vector, the expression of TGF-␤1 was dramatically suppressed in the obstructed kidneys ( Figure  7a ). At day 14 after ureteral obstruction, renal TGF-␤1 level was repressed by more than 85% following HGF plasmid injections (Figure 7a) .
We also investigated the expression of TGF-␤ type I receptor (T␤R-I) in the obstructed kidneys. Western blot analyses revealed that the type I receptor of TGF-␤ was significantly increased in the obstructed kidneys after UUO, compared with that in control, sham-operated kidney (Figure 7b ). This induction of T␤R-I in the obstructed kidneys occurred at day 3 following UUO and increased thereafter. Administration of exogenous HGF plasmid significantly inhibited TGF␤R-I expression in the obstructed kidneys (Figure 7b ). At day 7 after UUO, renal T␤R-I abundance was repressed by 60% following delivery of human HGF plasmid vector. A less extent inhibition of T␤R-I expression was also observed at day 14 in the obstructed kidneys after HGF gene transfer (Figure 7b ).
Discussion
HGF is a potent regenerative factor playing an important role in promoting tubular repair and tissue regeneration after acute renal injury induced by either ischemic or nephrotoxic insults. 5, 6, 23 However, its potential role in tissue repair following chronic renal injury remains poorly defined and arguably controversial. 15, 24 In this report, we demonstrate that delivery of exogenous HGF gene via systemic administration of naked plasmid vector induces renal Erk-1/2 kinases activation, inhibits ␣SMA expression and myofibroblast activation, attenuates renal interstitial fibrosis, and suppresses TGF-␤1 and its type I receptor expression in the obstructed kidneys after UUO. These results establish that HGF gene transfer is beneficial to the diseased kidneys by blocking tissue fibrogenesis following chronic insult caused by ureteral obstruction. Developing a gene therapy strategy to allow the persistent expression of HGF in vivo could be an efficient and economical way to deliver the therapeutic HGF to the diseased kidneys. This notion is supported by the observation that exogenous HGF protein is short-lived due to the rapid clearance by liver in vivo. 19 Based on the types of delivery systems, the current strategies to deliver a foreign gene in vivo can be divided into two distinct groups: nonviral vector and viral vectors. The virusbased vector systems, including retrovirus, adenovirus and adeno-associated virus, have their own inherent limitations, such as inability to infect non-proliferating cells for some or induction of severe host immune response for others. 25, 26 Using nonviral, naked plasmid vector, we adapt a hydrodynamics-based in vivo gene transfer strategy by systemic administration of the plasmid, 27-29 which results in a high level of exogenous HGF protein in normal and the diseased kidneys (Figure 2) . 20 Given the fact that endogenous HGF level is typically below 4 ng/mg protein in normal kidney, 30 the amount of exogenous
Figure 6 Expression of exogenous HGF gene inhibits interstitial fibronectin expression. (a) Western blot shows inhibition of fibronectin expression in obstructed kidneys at different time points as indicated after intravenous injection of either pCMV-HGF or pcDNA3 plasmid. Kidneys (pool from five animals per group) were homogenized, and protein extracts separated on a SDS-polyacrylamide gel and immunoblotted with antibody against fibronectin. The same blot was stripped and reprobed with actin to confirm equal loading. (b, c) Representative micrographs show fibronectin deposition in the obstructed kidneys at day 14 after UUO. Much less fibronectin staining was observed in the obstructed kidneys receiving pCMV-HGF plasmid (c) compared with that receiving control pcDNA3 plasmid (b). Scale bar, 20 m.
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Figure 7 Exogenous HGF inhibits TGF-␤1 and TGF-␤ type I receptor expression in obstructed kidneys. (a) Specific ELISA demonstrates dramatic inhibition of renal TGF-␤1 protein expression in the obstructed kidneys at different time points following systemic administration of pCMV-HGF plasmid. Tissue TGF-␤1 was expressed as pg/mg total protein. Data are presented as mean ± s.e. (n = 5). *P Ͻ 0.01 versus sham-operated group. ‡P Ͻ 0.01 versus UUO + pcDNA3 group. (b) Western blot shows the protein levels of type I TGF-␤ receptor (T␤R-I) in the obstructed kidneys at 3, 7 and 14 days following injection of either pCMV-HGF or pcDNA3 plasmid. Kidneys (pool from five animals per group) were homogenized, and whole tissue extracts immunoblotted with a specific anti-T␤R-I antibody. The same blot was stripped and reprobed with actin to confirm equal loading.
HGF obtained after intravenous injection of naked plasmid is both quite impressive and therapeutically effective. This HGF gene delivery approach has several obvious advantages. First, it is easy to prepare a large amount of HGF plasmid vector. Second, the injection procedure itself is simple and convenient without involvement of any surgical procedures as seen by renal artery and retrograde uerteric infusions. 25, 31 Third, delivery of plasmid vector, as well as HGF expression is proven to be safe in vivo. 20 Fourth, the duration of HGF expression in vivo is controllable via repeated administrations. Taken together, this approach represents a simple, efficient, novel strategy to deliver the therapeutic HGF to the diseased kidneys.
The results presented here are consistent with previous reports demonstrating that endogenous HGF tends to preserve normal kidney structure and functions in animals with chronic renal disease. 17, 18 Using two different animal model systems, we 17 and Mizuno et al 18 independently show that blocking of HGF signaling with neutralizing antibody markedly promotes the onset and progression of chronic renal fibrosis and kidney dysfunctions, suggesting that HGF activation in the diseased conditions is part of the tissue healing response that leads to attenuation of pathological lesions following chronic injuries. However, phenotypes with tumorigenesis and chronic renal failure are also reported in a transgenic mouse strain over-expressing HGF under metallothionein promoter. 24 This paradoxical disparity to the actions of HGF in the kidney is not fully understood. One explanation could be due to the inherent nature of de novo ubiquitous HGF expression and/or random chromosomal insertions associated with transgenic model. In accordance with this, the HGF transgenic mice develop both polycystic and glomerular lesions, similar to that described in mice with other diverse transgenes including HIV type 1, IL-6, c-erb-2 or c-Myc, suggesting that a nonspecific mechanism might be responsible for renal disease in these mice. 24 This view is further supported by the fact that there is no correlation between kidney pathology and HGF levels in these mice. 24 Of note, no renal lesion is reported in other HGF transgenic mouse lines recently developed independently in different laboratories. [32] [33] [34] Delivery of HGF gene in vivo significantly inhibits expression of ␣SMA, an indicative marker for renal myofibroblast cells. Activation of myofibroblasts has long been considered as a hallmark and valuable predictor for the progression of renal fibrogenesis both in animal models and in patients. 35 Although these myofibroblasts are generally presumed to derive from local activation of residential fibroblasts under diseased conditions, evidence suggests that these cells may also derive from tubular epithelial cells via a process known as epithelial to mesenchymal transition. 36, 37 Consistent with this view, our preliminary results show that TGF-␤1 can induce ␣SMA expression in both cultured renal interstitial fibroblasts and tubular epithelial cells in vitro (unpublished data). Regardless of the mechanisms, the fact that exogenous HGF inhibits myofibroblast activation in the obstructed kidneys underscores that exogenous HGF precisely targets a key event, the activation of principal matrix-producing cells, during renal fibrogenesis.
The mechanism underlying HGF inhibition of renal fibrosis remains unclear at this stage. The observation that HGF inhibits TGF-␤1 and its type I receptor may provide significant insight into the molecular mechanism beneath the anti-fibrogenic actions of HGF. TGF-␤1 is a well-characterized pro-fibrogenic cytokine whose expression is markedly up-regulated in most, if not all, animal models of chronic renal diseases. 38, 39 The diverse array of the biological actions of TGF-␤1 is mediated through the transmembrane type I (T␤R-I) and type II (T␤R-II) Ser/Thr kinase receptors. 40 Ligand binding triggers T␤R-II phosphorylation, resulting in the activation of T␤R-I kinase, which then phosphorylates Smad proteins and propagates signals to the nucleus to mediate gene response. 41 The simultaneous induction of both TGF-␤1 and its type I receptor in the obstructed kidneys likely highlights the importance of this pair of signaling system in the pathogenesis of chronic renal fibrosis.
Our results demonstrate a close correlation between inhibition of TGF-␤1 expression and attenuation of renal fibrosis in the obstructed kidneys following systemic administration of exogenous HGF plasmid. In view of the fact that over-expression of TGF-␤1 in animals causes renal fibrosis and that blocking of TGF-␤1 expression and its actions by diverse strategies attenuates tissue fibrosis in vivo, 39, 42 it is conceivable that exogenous HGF may ameliorate renal fibrosis by blocking TGF-␤1 signaling. Consistent with this, we show that exogenous HGF activates Erk1/2 kinases in the obstructed kidneys ( Figure  2 ), and such activation of Erk1/2 has been reported to lead to the blockage of Smad nuclear translocation and subsequent signaling. 43 However, the possibility remains that the suppression of TGF-␤1 axis by HGF may just reflect the attenuation of renal fibrosis, rather than being the underlying mechanism. The resolution of this issue has to await further experimentation to delineate the cause-effect relationship between HGF expression and inhibition of the TGF-␤ axis. Nevertheless, the fact that exogenous HGF expression induces down-regulation of both TGF-␤1 and its type I receptor in the obstructed kidneys per se may imply the potent anti-fibrogenic ability of HGF in vivo.
Materials and methods
Animals
Male CD-1 mice weighing at 18-22 g were purchased from Harlan Sprague Dawley (Indianapolis, IN, USA). They were housed in the animal facilities of the University of Pittsburgh Medical Center with free access to food and water. Animals were treated humanely using approved procedures in accordance with the guidelines of the Institutional Animal Use and Care Committee of National Institutes of Health at the University of Pittsburgh School of Medicine. Unilateral ureteral obstruction (UUO) was performed using an established procedure. 44 Briefly, under general anesthesia, complete ureteral obstruction was performed by double-ligating the left ureter using 4-0 silk following a midline abdominal incision. Sham-operated mice had their ureters exposed and manipulated, but not ligated.
Plasmid injection
The recombinant human HGF expression plasmid (pCMV-HGF) that contains the full-length human HGF cDNA driven under a human cytomegalovirus (CMV) promoter was cloned as described previously. 45 The empty expression plasmid vector pcDNA3 was purchased from Invitrogen (San Diego, CA, USA). Plasmid DNA was administered into mice by a hydrodynamicbased gene transfer technique via rapid injection of a large volume of DNA solution through the tail vein, as previously described. 20, 27 Briefly, 20 g of plasmid DNA was diluted in 1.6 ml of saline and injected via the tail vein into the circulation within 5-10 s. Mice were injected with pCMV-HGF plasmid before (day −1) and after (days 3 and 7) UUO, respectively (Figure 1a) . Control UUO mice were injected with 20 g of empty vector pcDNA3 plasmid at the same time points in an identical manner. Groups of mice (n = 5) were killed at 3, 7 and 14 days after UUO, respectively, and the kidneys were removed. One part of the kidneys was fixed in 10% phosphate-buffered formalin for histologic studies after paraffin embedding. Another part was immediately frozen in Tissue-Tek OCT compound for cryosection. The remaining kidneys were snap-frozen in liquid nitrogen and stored at −80°C for protein extractions.
Determination of HGF levels by ELISA For measurement of tissue HGF level, kidneys from mice were homogenized in the HGF extraction buffer containing 20 mm Tris-HCl, pH 7.5, 2 m NaCl, 0.1% Tween-80, 1 mm EDTA and 1 mm PMSF, as described previously. 20 After centrifugation at 19 000 g for 20 min at 4°C, the supernatant was recovered for determination of HGF using an ELISA method. This assay utilizes a sandwich method consisting of three steps of antigen-antibody reactions. Briefly, the 96-well microtitre plates (NuncImmuno Module, Fisher Scientific, Pittsburgh, PA, USA) were incubated with 50 l of uncoupled monoclonal anti-HGF antibody (H14) per well diluted in 50 mm Tris HCl, pH 8.0 at a final concentration of 1.5 g/ml at room temperature for 16 h. H14 anti-human HGF antibody was prepared using a standard protocol of hybridoma technology as described previously. 20 This antibody could detect human HGF protein, but not rodent HGF in an ELISA assay, in Western blotting, and in immunohistochemical staining. 20 The plates were washed three times with PBS containing 0.05% Tween 20, pH 7.4, and blocked with 200 l of blocker solution (PBS containing 1% BSA) at room temperature for 2 h. The plates were extensively washed five times with PBS containing 0.05% Tween 20 and kept at 4°C. Fifty l aliquots of standard human HGF solution or tissue samples were added to the wells and incubated for 2 h at room temperature. After extensive washing, a 100 l aliquot of biotinylated goat anti-human HGF polyclonal antibody (purchased from R&D Systems, Minneapolis, MN, USA) at a dilution of 1:2000 was added, and the plates were incubated for another 2 h. Following washing, they were then incubated with 100 l of horseradish peroxidase (HRP)-conjugated streptavidin (Zymed Laboratories, South San Francisco, CA, USA) at a dilution of 1:20000, and subsequently with enzyme substrate solution containing 0.1 mg/ml of tetramethylbenzidine and 0.006% H 2 O 2 in 0.1 m sodium citrate, pH 6.0. The plates were allowed to stand for 30 min at room temperature, and the reaction was stopped by addition of 50 l 4 N H 2 SO 4 . Absorbance was read at 405 nm by an automatic Emax Precision Microplate Reader (Molecular Devices, Sunnyvale, CA, USA). Samples were diluted if necessary to give an optical density that was within the linear portion of the standard curve. Total protein levels were determined using a bicinconinic-acid (BCA) protein assay kit (Sigma, St Louis, MO, USA) with BSA as a standard. The concentration of HGF in kidneys was expressed as nanograms per milligram total protein.
Western blot analysis
For detection of human HGF protein levels, total tissue protein extracts as described above for ELISA assay were Gene Therapy used for Western blot analyses. For detection of other proteins such as Erk 1/2, and ␣SMA by immunoblotting, kidney tissues were homogenized by a polytron homogenizer (Brinkmann Instruments, Westbury, NY, USA) in RIPA lysis buffer (1% NP40, 0.1% SDS, 100 g/ml PMSF, 0.5% sodium deoxycholate, 1 mm sodium orthovanadate, 2 g/ml aprotinin, 2 g/ml antipain, and 2 g/ml leupeptin in PBS) on ice, and the supernatants were collected after centrifugation at 13 000 g at 4°C for 20 min. Protein concentration was determined using a BCA protein assay kit (Sigma), and tissue lysates were mixed with an equal amount 2 × SDS loading buffer (100 mm Tris-HCl, 4% SDS, 20% glycerol, and 0.2% bromophenol blue), as described previously. 30 Samples were heated at 100°C for 5-10 min before loading and separated on precast 10% or 5% SDS-polyacrylamide gels (BioRad, Hercules, CA, USA). The proteins were electrotransferred to a nitrocellulose membrane (Amersham, Arlington Heights, IL, USA) in transfer buffer containing 48 mm Tris-HCl, 39 mm glycine, 0.037% SDS, and 20% methanol at 4°C for 1 h. Nonspecific binding to the membrane was blocked for 1 h at room temperature with 5% Carnation nonfat milk in TBS buffer (20 mm Tris-HCl, 150 mm NaCl, and 0.1% Tween 20) . The membranes were then incubated for 16 h at 4°C with various primary antibodies in blocking buffer containing 5% milk. The monoclonal anti-HGF antibody (H14) was diluted at a final concentration of 2 g/ml. The phospho-specific Erk1/2 antibody that detects Erk1/2 only when phosphorylated at specific sites was obtained from New England BioLabs (Beverly, MA, USA). The Erk1/2 antibody that detects total Erk1/2 (phosphorylation state-independent) and ␣SMA antibody were purchased from Sigma. The anti-fibronectin antibody was obtained from Transduction Laboratories (Lexington, KY, USA). The rabbit polyclonal anti-actin antibody was purchased from Santa Cruz Biochemicals (Santa Cruz, CA, USA). Following extensive washing three times, the membranes were then incubated with horseradish peroxidase-conjugated secondary antibody (BioRad) for 1 h at room temperature in 1% nonfat milk. The signals were visualized by the enhanced chemiluminescence system (ECL; Amersham). Quantitation was performed by measuring the intensity of the hybridization signals using NIH Image analysis software. 30 
Morphological studies
Tissue sections from the mice were prepared at 4 m thick by a routine procedure. Sections were stained with hematoxylin/eosin for general histology. Renal morphological injury, as characterized by tubular dilution with epithelial atrophy and interstitial expansion with matrix deposition, were scored in a blind fashion based on a scale of 0 (absent), 1 (mild), 2 (moderate), and 3 (severe), as previously reported. 18 The overall mean scores were calculated based on individual values, which were determined on 10 fields per mouse, five mice per group.
Immunofluorescence microscopy Kidney cryosections were prepared and fixed for 5 min in PBS containing 3% paraformaldehyde, and then incubated with primary antibodies against fibronectin and collagen I, respectively, in PBS containing 1% BSA overnight at 4°C. Sections were then incubated for 1 h with fluorescein-conjugated secondary antibodies at a dilution of 1:200 in PBS containing 5% BSA, before being washed extensively with PBS. As a negative control, the primary antibody was replaced with nonimmune IgG and no staining occurred. Slides were mounted with anti-fade mounting media (Vector Laboratories, Burlingame, CA, USA) and viewed with a Nikon Eclipse E600 Epi-fluorescence microscope equipped with a digital camera (Melville, NY, USA). The intensity of the staining was scored in a blinded fashion based on a scale of 0 (absent), 1 (weak), 2 (moderate), and 3 (strong) in 10 randomly chosen non-overlapping high power (× 400) fields for each mouse. The overall mean scores were calculated based on individual values, which were determined on 10 fields per mouse, five mice per group.
Determination of tissue TGF-␤1 levels by ELISA
For measurement of renal TGF-␤1 levels, kidneys from mice were homogenized, and the supernatant was recovered following centrifugation at 19 000 g for 20 min at 4°C. Kidney tissue TGF-␤1 level was determined by using a commercial Quantikine TGF-␤1 ELISA kit in accordance with the protocol specified by the manufacturer (R&D Systems). This kit measures the abundance of active TGF-␤1 protein that binds to its soluble type II receptor precoated on to a microplate. Total protein levels were determined using a BCA protein assay kit as described above. The concentration of TGF-␤1 in kidneys was expressed as picograms per milligram total protein.
Statistical analysis
Animals were randomly assigned to control and treatment groups. Statistical analysis of the data was performed by Student's t test using SigmaStat software (Jandel Scientific, San Rafael, CA, USA). A P value of less than 0.05 was considered significant.
